Chapter 86 Goldman Sachs in Action
The first phase of Guangjia Technology’s human hibernation technology experiment is almost over.
No adverse reactions have occurred in existing samples. This does not mean that there are no adverse reactions, but that the probability is very small, less than one in 100,000.
Because human hibernation technology is a new field, Americen has obtained specific data from channels in China, and Goldman Sachs began to make plans after obtaining the data.
They believe that the adverse reactions are so low that they can be widely promoted in Ameliken.
In the early stage, human experiments can be used as an excuse to carry out experiments among illegal immigrants. This can not only save the cost of experiments, but the cost of serious drug testers is much higher than that of illegal immigrants.
Even if the experimental site is placed in India or South Africa, the cost is still very high. This industry is already very standardized, and multinational companies have strict requirements. If you are not careful, you will be fined hugely.
The Ah Sans are watching eagerly and are worried about having no financial resources.
Illegal immigrants are different. Even if something happens, they will be noisy in the media for two days at most.
Goldman Sachs has another plan, which is to try to explore whether human hibernation technology is addictive and whether it can extend human life.
The life extension here refers to whether the continuous human hibernation and three days of waking up and sleeping for three days can lead to slower aging than normal people.
Such experiments can only be carried out under the guise of humanistic care.
"Mr. Chen, in order to promote the introduction of human hibernation technology into Amerikan, we have tried many ways to lobby the White House.
Currently we have found some entry points, but we need light armor The cooperation of technology.”
Goldman Sachs is in action.
Lobbyists in Washington are working hard to persuade senators on Capitol Hill to turn a blind eye to human hibernation technology, and at the same time mobilize the power of the country to promote human hibernation technology.
Goldman Sachs executives in Greater China are also taking action, and they are persuading Chen Yuanguang.
“We need a new cooperation model. In Europe, South Africa, and Southeast Asia, Guangjia Technology’s model of establishing branches is feasible, and Guangjia Technology can obtain most of the profits.
< br>Not in North America. Washington is naturally wary of Chinese companies, let alone such sensitive technology as Guangjia Technology, which involves the human brain
You know, Capitol Hill. The congressmen can make up any excuses, TikTok will control what Americans are thinking
Huawei's equipment will affect safety, so won't Guangjia Technology's human hibernation technology not?
In that case, Guangjia Technology will not only be unable to enter the American market, it will not even be able to enter the European market.
We hope that through cooperation, Guangjia Technology will hide behind the scenes, penetrate through layers of equity, package it into a biopharmaceutical company in Maple Leaf Country, and cooperate with Arcadia.
Acadia will eventually conduct clinical trials and equipment sales in North America. " said Carla Mangon, who was previously the global head of climate strategy at Goldman Sachs and is now the executive responsible for strategic investments at Goldman Sachs China.
Chen Yuanguang asked: "Why Arcadia and not Merck? ”
Carla Mangon's heart trembled. Chen Yuanguang's ability to tell Merck exceeded her expectations.
In the eyes of the outside world, Goldman Sachs and Pfizer have the best relationship. The two parties have long-term cooperation. Goldman Sachs has always recommended Pfizer on various occasions.
In fact, only experts know that Goldman Sachs’ first choice for pharmaceutical stocks has always been Merck. The relationship between Goldman Sachs and Merck is far closer than that of Pfizer. MSD.
As a Chinese, Chen Yuanguang has never been on Wall Street. It is very rare to be able to dig up information to this level.
Kara Mangon adjusted her mood: "For human hibernation technology to be rolled out across the United States, the company needs to have a certain size. Not just any company can do this. And because it still involves Chinese technology after all, The products also come from China, which involves risks, and Merck is too big.
Arcadia has been deeply involved in innovative drugs all year round. The innovative drugs they previously produced were related to mental illness and Alzheimer's disease. Their promotion of human hibernation technology and clinical trials are very relevant. In addition, its market value is 20 With just over 100 million US dollars, even if this shell is given up, the loss is acceptable. ”
After listening, Chen Yuanguang couldn’t help but lamented that Goldman Sachs was so sophisticated and so powerful that it could easily find such suitable white gloves to do this.
Instead of It’s him, he can’t do it no matter how long he takes.
“I understand, I need time to think about it.
How do we divide it between us? "
Kara Mangon said: "If you are willing to transfer technology one-time, the price can be whatever you want.
If there is no technology transfer, then the price will be based on equipment purchase. "
China will obviously not agree to the technology transfer, "Then it's about equipment procurement.
This matter must be kept secret, and there must be no traces of this technology or light armor technology on the surface. ”
The reason why Chen Yuanguang is so cautious is that obviously direct sales have the greatest benefits. With the equipment sales model, profits are limited no matter how high the unit price is.
Direct sales are a steady stream of cash cows.
Once the cooperation model between Guangjia Technology and American is leaked, other countries and regions will also require the same cooperation model, which will seriously affect the interests of Guangjia Technology.
Kara Mangon: "Obviously, the exposure of this matter will have a greater impact on us.
I will help you arrange the operating procedures and other matters for the companies in the middle.
At that time, the account will go to the Mexican branch's account. ”
This means the source of profits of the Mexican branch, including the direct sales of human hibernation in Mexico and the profits from the sale of North American equipment.
Chen Yuanguang realized that the Donkey Party and Goldman Sachs were fully confident that Mexico is completely in control.
“Okay! ”
Some Guangjia Technology can also make money from this kind of cooperation, but it is less than direct operation, which is better than nothing.
Moreover, if Goldman Sachs did not cooperate, Goldman Sachs would definitely seriously affect the operation of Guangjia Technology in overseas markets, so Chen Yuanguang agreed simply.
Kara Mangon stretched out her hand to shake hands with Chen Yuanguang: "It's a pleasure to cooperate."
The cold touch made Chen Yuanguang realize that the white-bone man in front of him was a femme fatale. He was also curious about human hibernation. How will technology, under the control of Goldman Sachs, affect Amerikan?
“When will your company go public?” Lin Qinghua asked.
It’s another New Year. Chen Yuanguang has been preparing for the establishment of the Guangjia Aerospace R&D Center in Pengcheng at the end of the year. As soon as the New Year arrives, he returns directly to Yangcheng.
Lin Jia is returning to Hangzhou for the New Year. Once he returns, he will face questioning from relatives and friends. They don't care what you want to answer or what you don't want to answer. They only care about what they want to ask.
“I don’t know, it depends on Chen Yuanguang’s intention, and it also depends on how the talks with institutions and the China Securities Regulatory Commission go. Going public is not something I can do if I want to.” Lin Jia said helplessly.
Slowly making up for the last two days, today there are still two chapters of 6k
(End of this chapter)